On Tuesday, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), added 2.89% and closed at $14.28 in the last trading session. The last trading range of the stock ranges between $12.49 and $14.38. Halozyme Therapeutics, Inc. (HALO), an oncology biotech developing novel oncology and drug-delivery therapies, and Genentech, a member of the Roche Group, recently declared a contract to collaborate on clinical studies evaluating up to eight different tumor types starting in 2017.
The first study will be a Phase 1b/2 open-label, multi-arm randomized global study, led by Genentech to evaluate their cancer immunotherapy Tecentriq® (atezolizumab), an anti-PD-L1 monoclonal antibody, in combination with Halozyme’s investigational drug, PEGPH20 in six tumor types. Halozyme will supply drug only for the Genentech study. This study will have an initial focus on gastrointestinal malignancies, counting pancreatic and gastric cancers.
The second study will be a Phase 1b open-label randomized study led by Halozyme to assess Tecentriq in combination with PEGPH20 and chemotherapy in advanced or metastatic biliary and gallbladder cancers.
Celgene Corporation (NASDAQ:CELG), jumped 0.19% and closed at $120.91 in the last trading session. The last trading range of the stock ranges between $118.17 and $121.65. The company’s Market capitalization is $94.70 Billion with the total Outstanding Shares of 775.20 Million. Celgene Corporation (CELG) recently declared findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. The trial met its primary endpoint of noteworthyimprovement in the proportion of patients achieving an ACR20 response at week 16 with OTEZLA as compared to placebo in patients with active psoriatic arthritis who have not formerly been treated with a biologic therapy.
The ACTIVE trial randomized 219 patients who may have had one prior conventional therapy and were not formerly treated with a biologic to either OTEZLA 30 mg twice daily (n=110) or placebo (n=109). An objective of the study was to determine the clinical effects of OTEZLA contrast with placebo, by examining efficacy outcomes at earlier time points than in previous studies.